Takayuki Tokunaga

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 8

Top Topics

Liver Metastases

Metastatic Colorectal Cancer

Top Venues

Cancer medicine

Hepatology research : the official journal of the Japan Society of Hepatology

This page only lists publications with an associated author ORCID identifier.

Publications

Takanori Suzuki, Kentaro Matsuura, Yuta Suzuki, Fumihiro Okumura, Yoshihito Nagura, Satoshi Sobue, Sho Matoya, Tomokatsu Miyaki, Yoshihide Kimura, Atsunori Kusakabe, Satoshi Narahara, Takayuki Tokunaga, Katsuya Nagaoka, Keita Kuroyanagi, Hayato Kawamura, Kayoko Kuno, Kei Fujiwara, Shunsuke Nojiri, Hiromi Kataoka, Yasuhito Tanaka
Serum CXCL10 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced BCLC stage C hepatocellular carcinoma: A multicenter analysis. Cancer medicine (2023)
Yoko Yoshimaru, Katsuya Nagaoka, Kentaro Tanaka, Satoshi Narahara, Hiroki Inada, Sotaro Kurano, Takayuki Tokunaga, Estuko Iio, Takehisa Watanabe, Hiroko Setoyama, Masakuni Tateyama, Koji Yoshida, Takuya Tsunoda, Yusuke Nakamura, Motohiko Tanaka, Yutaka Sasaki, Yasuhito Tanaka
A randomized phase I / II study of vascular endothelial growth factor receptor peptide vaccines for patients with hepatocellular carcinoma. Hepatology research : the official journal of the Japan Society of Hepatology (2023)
Takanori Suzuki, Kentaro Matsuura, Yuta Suzuki, Fumihiro Okumura, Yoshihito Nagura, Satoshi Sobue, Sho Matoya, Tomokatsu Miyaki, Yoshihide Kimura, Atsunori Kusakabe, Satoshi Narahara, Takayuki Tokunaga, Katsuya Nagaoka, Keita Kuroyanagi, Hayato Kawamura, Kayoko Kuno, Kei Fujiwara, Shunsuke Nojiri, Hiromi Kataoka, Yasuhito Tanaka
Serum CXCL10 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced BCLC stage C hepatocellular carcinoma: A multicenter analysis. Cancer medicine (2023)
Takayuki Tokunaga, Masakuni Tateyama, Yasuteru Kondo, Satoshi Miuma, Shiho Miyase, Kentaro Tanaka, Satoshi Narahara, Hiroki Inada, Sotaro Kurano, Yoko Yoshimaru, Katsuya Nagaoka, Takehisa Watanabe, Hiroko Setoyama, Kotaro Fukubayashi, Motohiko Tanaka, Yasuhito Tanaka
Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular Carcinoma. Cancers 15 (5) (2023)
Takayuki Tokunaga, Masakuni Tateyama, Yasuteru Kondo, Satoshi Miuma, Shiho Miyase, Kentaro Tanaka, Satoshi Narahara, Hiroki Inada, Sotaro Kurano, Yoko Yoshimaru, Katsuya Nagaoka, Takehisa Watanabe, Hiroko Setoyama, Kotaro Fukubayashi, Motohiko Tanaka, Yasuhito Tanaka
Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular Carcinoma. Cancers 15 (5) (2023)
Takanori Suzuki, Kentaro Matsuura, Yuta Suzuki, Fumihiro Okumura, Yoshihito Nagura, Satoshi Sobue, Sho Matoya, Tomokatsu Miyaki, Yoshihide Kimura, Atsunori Kusakabe, Satoshi Narahara, Takayuki Tokunaga, Katsuya Nagaoka, Keita Kuroyanagi, Hayato Kawamura, Kayoko Kuno, Kei Fujiwara, Shunsuke Nojiri, Hiromi Kataoka, Yasuhito Tanaka
Serum CXCL10 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced BCLC stage C hepatocellular carcinoma: A multicenter analysis. Cancer medicine (2023)
Takanori Suzuki, Kentaro Matsuura, Yuta Suzuki, Fumihiro Okumura, Yoshihito Nagura, Satoshi Sobue, Sho Matoya, Tomokatsu Miyaki, Yoshihide Kimura, Atsunori Kusakabe, Satoshi Narahara, Takayuki Tokunaga, Katsuya Nagaoka, Keita Kuroyanagi, Hayato Kawamura, Kayoko Kuno, Kei Fujiwara, Shunsuke Nojiri, Hiromi Kataoka, Yasuhito Tanaka
Serum CXCL10 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced BCLC stage C hepatocellular carcinoma: A multicenter analysis. Cancer medicine 13 (1) (2023)
Takayuki Tokunaga, Masakuni Tateyama, Kentaro Tanaka, Satoshi Narahara, Hiroki Inada, Sotaro Kurano, Sanae Hayashi, Yoko Yoshimaru, Katsuya Nagaoka, Takehisa Watanabe, Hiroko Setoyama, Motohiko Tanaka, Yasuhito Tanaka
Optimal management of lenvatinib therapy for patients with unresectable hepatocellular carcinoma by balancing the therapeutic effect with the relative dose intensity. Hepatology research : the official journal of the Japan Society of Hepatology (2021)